Updates are available Correction dated 2020-12-15
Click to view Correction: https://doi.org/10.1007/s00228-020-03067-9
-
Authors
Mueller-Schoell, Anna
Groenland, Stefanie L.
Scherf-Clavel, Oliver
van Dyk, Madelé
Huisinga, Wilhelm
Michelet, Robin
Jaehde, Ulrich
Steeghs, Neeltje
Huitema, Alwin D.R.
Kloft, Charlotte http://orcid.org/0000-0001-9344-8514
-
Funding
Funding for this research was provided by:
Freie Universität Berlin
- License Information
-
More Information
Article History
Received: 2 July 2020
Accepted: 1 October 2020
First Online: 9 November 2020
Change Date: 15 December 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00228-020-03067-9
Compliance with ethical standards
:
: CK and WH report grants from an industry consortium (AbbVie Deutschland GmbH & Co. KG, Astra Zeneca, Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal GmbH, F. Hoffmann-La Roche Ltd., Merck KGaA and Sanofi) for the PharMetrX PhD program. CK reports grant for the Innovative Medicines Initiative-Joint Undertaking (‘DDMoRe’). CK and RM report grants from the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (JPIAMR), all outside the submitted work. OS reports endowed professorship grant (Horphag research Ltd) and funding for the project ‘Individualized cancer therapy with kinase inhibitors using drug monitoring – optimization by minimally invasive at-home sampling’ (Hector Stiftung II gGmbH). The remaining authors declare that the research was conducted in absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: Not applicable.
: Not applicable.
: Not applicable.
